Home / Pharma News

Pharma News

Boehringer Ingelheim loses patent battle with India’s Cipla

German pharmaceutical company Boehringer Ingelheim (Boehringer) has lost its patent on the Spiriva respiratory drug in India. The Indian patent office has agreed with the Indian drugmaker Cipla that Boehringer’s Spiriva patent was obvious and was not an invention under India’s patent laws.

Indian Government to launch own brand of generics

Not happy with its current control over the price of drugs in the country, the Indian Government has announced plans to launch its own brand of low cost generics.

Canada clamps down on companies failing to post drug shortage information

The Canadian Government has made it mandatory for drug companies to report actual and anticipated drug shortages. A voluntary system that had been in place was not working well enough, said the country’s Health Minister, Rona Ambrose.

Pfizer sets to lead biosimilars and generics markets

Pharma giant Pfizer has announced it is to buy injectable generics specialist and biosimilars maker Hospira for US$17 billion. The products acquired in the deal will be integrated into Pfizer’s generics unit, Global Established Pharmaceutical (GEP).

Mylan on track to acquire Abbott generics and expand role in women’s health

The European Commission (EC) has approved Mylan’s acquisition of Abbott Laboratories' Non-US Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM), subject to conditions. US-based generics manufacturer Mylan will have to sell off a number of its businesses in France, Germany, Ireland, Italy and UK in order to satisfy European Union merger regulations.

Actavis to buy UK generics maker Auden McKenzie

US generics maker Actavis announced on 26 January 2015 that it had agreed to buy UK generics maker Auden McKenzie. The deal will propel Actavis into the top position in the UK for generics suppliers, placing it in third position in the UK overall.

Amgen’s approach in the biosimilars market

Biotech giant Amgen now has a biosimilars programme that includes nine different molecules [1]. A representative from Amgen has spoken to GaBI about the company’s venture into biosimilars [2].

Top 10 most read GaBI Online articles in 2014

2014 was once again a busy year for biosimilars, ranging from revision of regulatory guidelines to naming and extrapolation. Biosimilars remain the hot topic for GaBI Online during 2014 and, in fact, all 10 of the most read articles concern biosimilars.

Cipla makes deal with Serum Institute for vaccines in Europe

India-based generics maker Cipla announced on 20 November 2014 that it had signed a deal with the Serum Institute of India (Serum Institute) to distribute vaccines in Europe.

Actavis buys Allergan and joins pharma top 10

On 17 November 2014, US generics maker Actavis announced that the company had made a deal to acquire botox-maker Allergan for US$66 billion.

Generics News Research General


Biosimilars News Research General